AtriCure, Inc. 10-Q

Item 1. Financial Statements ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Per Share Amounts) (Unaudited) June 30, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 167,786 $ 167,428 Accounts receivable, less allowance for credit losses of $ 1,000 and $ 750 79,981 66,653 Inventories 83,925 78,492 Prepaid and other current assets 13,839 9,944 Total current assets 345,531 322,517 Property and equipment, net 42,422 39,123 Operating lease right-of-use assets 6,069 6,868 Intangible assets, net 43,258 48,026 Goodwill 234,781 234,781 Other noncurrent assets 4,582 2,864 Total Assets $ 676,643 $ 654,179 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 35,850 $ 25,310 Accrued liabilities 42,893 53,089 Other current liabilities 3,173 3,121 Total current liabilities 81,916 81,520 Long-term debt 61,000 61,865 Finance and operating lease liabilities 10,048 11,516 Other noncurrent liabilities 7,246 7,343 Total Liabilities 160,210 162,244 Commitments and contingencies (Note 8) Stockholders’ Equity: Common stock, $ 0.001 par value, 90,000 shares authorized and 50,863 and 49,792 issued and outstanding 51 50 Additional paid-in capital 920,421 904,522 Accumulated other comprehensive income 101 566 Accumulated deficit ( 404,140 ) ( 413,203 ) Total Stockholders’ Equity 516,433 491,935 Total Liabilities and Stockholders’ Equity $ 676,643 $ 654,179 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue $ 153,604 $ 136,139 $ 294,853 $ 259,759 Cost of revenue 34,975 34,657 66,913 65,649 Gross profit 118,629 101,482 227,940 194,110 Operating expenses: Research and development expenses 26,402 29,284 50,637 51,812 Selling, general and administrative expenses 82,562 78,390 167,112 154,444 Total operating expenses 108,964 107,674 217,749 206,256 Income (loss) from operations 9,665 ( 6,192 ) 10,191 ( 12,146 ) Other income (expense): Interest expense ( 1,318 ) ( 1,490 ) ( 2,658 ) ( 2,906 ) Interest income 1,179 941 2,424 1,983 Other income (expense) ( 100 ) 812 ( 137 ) 632 Income (loss) before income tax expense 9,426 ( 5,929 ) 9,820 ( 12,437 ) Income tax expense 471 261 757 500 Net income (loss) $ 8,955 $ ( 6,190 ) $ 9,063 $ ( 12,937 ) Net income (loss) per share Basic net income (loss) per share $ 0.18 $ ( 0.13 ) $ 0.19 $ ( 0.27 ) Diluted net income (loss) per share $ 0.18 $ ( 0.13 ) $ 0.18 $ ( 0.27 ) Weighted average shares outstanding Basic 48,667 47,721 48,501 47,557 Diluted 48,868 47,721 49,094 47,557 Comprehensive income (loss): Foreign currency translation adjustment ( 126 ) 979 ( 465 ) 1,784 Net income (loss) 8,955 ( 6,190 ) 9,063 ( 12,937 ) Comprehensive income (loss), net of tax $ 8,829 $ ( 5,211 ) $ 8,598 $ ( 11,153 ) See accompanying notes to condensed consolidated financial statements. 4 Table of Contents ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (In Thousands) (Unaudited) Three-Month Period Ended June 30, 2025 Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance—March 31, 2025 49,493 $ 49 $ 863,302 $ ( 408,502 ) $ ( 230 ) $ 454,619 Impact of equity compensation plans 198 1 15,082 — — 15,083 Other comprehensive income — — — — 979 979 Net loss — — — ( 6,190 ) — ( 6,190 ) Balance—June 30, 2025 49,691 $ 50 $ 878,384 $ ( 414,692 ) $ 749 $ 464,491 Three-Month Period Ended June 30, 2026 Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance—March 31, 2026 50,635 $ 51 $ 904,510 $ ( 413,095 ) $ 227 $ 491,693 Impact of equity compensation plans 228 — 15,911 — — 15,911 Other comprehensive loss — — — — ( 126 ) ( 126 ) Net income — — — 8,955 — 8,955 Balance—June 30, 2026 50,863 $ 51 $ 920,421 $ ( 404,140 ) $ 101 $ 516,433 Six-Month Period Ended June 30, 2025 Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance—December 31, 2024 48,869 $ 49 $ 863,710 $ ( 401,755 ) $ ( 1,035 ) $ 460,969 Impact of equity compensation plans 822 1 14,674 — — 14,675 Other comprehensive income — — — — 1,784 1,784 Net loss — — — ( 12,937 ) — ( 12,937 ) Balance—June 30, 2025 49,691 $ 50 $ 878,384 $ ( 414,692 ) $ 749 $ 464,491 Six-Month Period Ended June 30, 2026 Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance—December 31, 2025 49,792 $ 50 $ 904,522 $ ( 413,203 ) $ 566 $ 491,935 Impact of equity compensation plans 1,071 1 15,899 — — 15,900 Other comprehensive loss — — — — ( 465 ) ( 465 ) Net income — — — 9,063 — 9,063 Balance—June 30, 2026 50,863 $ 51 $ 920,421 $ ( 404,140 ) $ 101 $ 516,433 See accompanying notes to condensed consolidated financial statements. 5 Table of Contents ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands) (Unaudited) Six Months Ended June 30, 2026 2025 Cash flows from operating activities: Net income (loss) $ 9,063 $ ( 12,937 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Share-based compensation expense 23,586 21,001 Depreciation 5,812 6,034 Amortization of intangible assets 4,768 4,221 Amortization of deferred financing costs 210 239 Acquired in-process research and development expense — 5,000 Other non-cash adjustments 1,177 311 Changes in operating assets and liabilities: Accounts receivable ( 13,780 ) ( 4,844 ) Inventories ( 5,641 ) ( 74 ) Other current assets ( 3,961 ) ( 1,482 ) Accounts payable 9,017 ( 45 ) Accrued liabilities ( 10,060 ) ( 5,832 ) Other noncurrent assets and liabilities ( 1,995 ) ( 1,001 ) Net cash provided by operating activities 18,196 10,591 Cash flows from investing activities: Purchases of property and equipment ( 7,618 ) ( 4,843 ) Acquisitions, including in-process research and development — ( 5,000 ) Proceeds from capital grant — 500 Net cash used in investing activities ( 7,618 ) ( 9,343 ) Cash flows from financing activities: Payments on debt, leases and financing obligation ( 1,528 ) ( 579 ) Payment of financing costs and debt fees ( 779 ) — Shares repurchased for payment of taxes on stock awards ( 11,756 ) ( 10,578 ) Proceeds from stock option exercises and employee stock purchase plan 4,070 4,251 Net cash used in financing activities ( 9,993 ) ( 6,906 ) Effect of exchange rate changes on cash and cash equivalents ( 227 ) 733 Net increase (decrease) in cash and cash equivalents 358 ( 4,925 ) Cash and cash equivalents—beginning of period 167,428 122,721 Cash and cash equivalents—end of period $ 167,786 $ 117,796 Supplemental cash flow information: Cash paid for interest $ 2,385 $ 2,574 Cash paid for taxes, net of refunds 1,053 882 Non-cash investing and financing activities: Accrued purchases of property and equipment 2,989 895 See accompanying notes to condensed consolidated financial statements. 6 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of the Business —The “Company” or “AtriCure” consists of AtriCure, Inc. and its wholly-owned subsidiaries. AtriCure is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, and sells its products to medical centers globally through both its direct sales force and distributors. Basis of Presentation —The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying interim financial statements are unaudited, but in the opinion of the Company’s management, contain all normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America (GAAP) applicable to interim periods. Certain information and footnote disclosures included in annual financial statements prepared in accordance with GAAP have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full year or for any future period. The accompanying interim financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. Except as discussed herein, there have been no changes in the Company's significant accounting policies for the six months ended June 30, 2026 as compared to the significant accounting policies described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. Use of Estimates —The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Actual results could differ from those estimates. Segments —The Company evaluates reporting segments in accordance with the Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) 280, "Segment Reporting". The chief operating decision maker for AtriCure is the Chief Executive Officer. The Company has one business activity and operates as one operating segment: the development, manufacture and sale of devices used by physicians in surgical procedures, designed primarily for the surgical ablation of cardiac tissue, the exclusion of the left atrial appendage and ablation of peripheral nerves to temporarily block pain. These devices are developed and marketed to a broad base of medical centers globally. Management considers all such sales to be part of the single operating segment. The Chief Executive Officer is regularly provided with consolidated expenses consistent with the presented consolidated statements of operations, accompanied by information about revenue by product type and geographic area, for purposes of allocating resources. Net income (loss) is the measure used in evaluating financial performance. Revenue by product type and geographic area is included in Note 9 – Revenue. The Company’s long-lived assets are located in the United States, except for $ 5,917 as of June 30, 2026 and $ 6,292 as of December 31, 2025 located primarily in Europe. 2. FAIR VALUE Fair value is defined as the exchange price that would be received for an asset or paid to settle a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure the fair value of assets and liabilities, the Company uses the following fair value hierarchy based on three levels of inputs: • Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. 7 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2026: Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Total Assets: Money market funds $ 157,082 $ — $ — $ 157,082 Total assets $ 157,082 $ — $ — $ 157,082 There were no changes in the levels or methodology of measurement of financial assets and liabilities during the three and six months ended June 30, 2026. The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2025: Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Total Assets: Money market funds $ 156,491 $ — $ — $ 156,491 Total assets $ 156,491 $ — $ — $ 156,491 Contingent Consideration. The Company’s contingent consideration arrangements arising from the SentreHEART acquisition obligate the Company to pay certain defined amounts to former shareholders of SentreHEART if specified milestones are met related to the aMAZE™ IDE clinical trial, including PMA approval and reimbursement for the therapy involving SentreHEART’s devices. The PMA approval milestone expired December 31, 2023, while the achievement period for the reimbursement milestone expires on December 31, 2026. The Company assessed the projected probability of payment during the contractual achievement periods as remote, resulting in no reported fair value as of June 30, 2026 and December 31, 2025. 3. INVENTORIES Inventories consist of the following: June 30, 2026 December 31, 2025 Raw materials $ 40,598 $ 39,052 Work in process 6,729 3,759 Finished goods 36,598 35,681 Total $ 83,925 $ 78,492 4. INTANGIBLE ASSETS The following table provides a summary of the Company’s intangible assets: June 30, 2026 December 31, 2025 Cost Accumulated Amortization Cost Accumulated Amortization Technology $ 46,470 $ 17,612 $ 46,470 $ 16,144 Patents 30,000 15,600 30,000 12,300 Total $ 76,470 $ 33,212 $ 76,470 $ 28,444 8 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) The following table summarizes the allocation of amortization expense of intangible assets: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Cost of revenues $ 1,650 $ 1,350 $ 3,300 $ 2,700 Research and development expenses 734 761 1,468 1,521 Total $ 2,384 $ 2,111 $ 4,768 $ 4,221 Future amortization expense is projected as follows: 2026 (excluding the six months ended June 30, 2026) $ 4,767 2027 10,435 2028 6,535 2029 2,935 2030 2,935 2031 and thereafter 15,651 Total $ 43,258 5. ACCRUED LIABILITIES Accrued liabilities consist of the following: June 30, 2026 December 31, 2025 Accrued compensation and employee-related expenses $ 35,580 $ 46,760 Sales returns and allowances 4,014 3,476 Other accrued liabilities 3,299 2,853 Total $ 42,893 $ 53,089 6. BORROWINGS AND FINANCING OBLIGATION Asset backed revolving credit facility. The Company has an asset-based credit facility (Credit Agreement) with JPMorgan Chase Bank, N.A. (JPMCB, also the administrative agent) and Silicon Valley Bank (a division of First-Citizen Bank and Trust Company). The Credit Agreement provides a $ 125,000 asset-based revolving credit facility (ABL Facility), and the Company may request an increase in the revolving commitment up to $ 40,000 (not to exceed a total of $ 165,000 ). A portion of the ABL Facility, limited to $ 5,000 , is available for the issuance of letters of credit by JPMCB or other financial institutions. JPMCB in its sole discretion, may create swingline loans by advancing floating rate revolving loans requested. Any such swingline loans will reduce availability under the ABL Facility on a dollar-for-dollar basis. On January 9, 2026, the Company entered into a First Amendment to Credit Agreement. The First Amendment provides a three-year extension of the term of the Credit Agreement, and all outstanding borrowings are due upon the maturity of the Credit Agreement on January 9, 2029. Subject to customary exceptions and restrictions, the Company may voluntarily prepay outstanding amounts under the ABL Facility at any time without premium or penalty. Any voluntary prepayments will not reduce lender commitments under the ABL Facility. The Credit Agreement contains mandatory prepayment provisions which require prepayment of amounts outstanding under the ABL Facility upon specified events or availability shortfall. The First Amendment provides for a reduction in the overall interest rate on loans under the ABL Facility and removes the minimum utilization financial covenant in addition to certain other loan administration updates. Following closing, the Company paid down $ 865 of borrowings. The First Amendment was treated as a debt modification. 9 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) As of June 30, 2026, the Company had total borrowings of $ 61,000 and had unused borrowing capacity of $ 62,750 under the ABL Facility. Future maturities of long-term debt are projected as follows: 2026 (excluding the six months ended June 30, 2026) $ — 2027 — 2028 — 2029 61,000 2030 — Total long-term debt, of which $ 61,000 is noncurrent $ 61,000 The ABL Facility is subject to a commitment fee of 0.37 % per annum of the daily available revolving commitment and paid on a quarterly basis. Outstanding amounts bear interest at a rate per annum equal to, at the Company's election: (i) an alternate base rate (ABR) plus an applicable margin or (ii) a term secured overnight financing rate (SOFR) plus an applicable margin. All swingline loans bear interest at a rate per annum equal to the ABR plus the applicable margin. Alternate base rate is equal to the greatest of Prime, the NYFRB Rate plus 0.50 % and the Term SOFR rate plus 1.00 %. The applicable margin on borrowings will adjust ranging from 1.25 % to 1.50 % per annum for ABR borrowings and from 2.25 % to 2.50 % per annum for Term SOFR borrowings determined by the average historical excess availability. As of June 30, 2026, the effective interest rate on the ABL Facility was 5.89 %. The ABL Facility is secured by the assets of the Company, consisting of personal, tangible or intangible property, including certain outstanding equity interests of the Company’s direct subsidiaries, subject to limitations specified in the Credit Agreement. The Credit Agreement contains customary representations and warranties, events of default and financial, affirmative and negative covenants for facilities of this type, including but not limited to financial covenants relating to a fixed charge coverage ratio, and restrictions on indebtedness, liens, investments and acquisitions, asset dispositions, specified agreements, restricted payments and prepayment of certain indebtedness. Financing obligation. In August 2025, the Company transferred legal ownership of a building and certain real property on its corporate headquarters campus in Mason, Ohio for cash consideration of $ 6,250 . Simultaneously, the Company entered into a contract to lease back the existing building and real property, as well as the planned building expansion space from the buyer-lessor. The buyer-lessor is financing the development and construction of the expansion of additional manufacturing and office space. During construction of the expansion, the Company will maintain occupancy and pay rent for the existing building. Upon construction completion, the expanded premises will be leased for fifteen years with three five-year options to renew. Annual rental payments will be calculated at an amount equal to 8 % of the construction costs and will escalate 3 % annually. Rental payments will be allocated between the existing and the expanded property based on the relative fair value upon construction completion. Expansion rental payments are projected to be $ 38,469 for the fifteen-year lease term and are expected to begin during the second half of 2026. The classification of the lease related to the expansion will be assessed upon completion of construction. Rental payments will be finalized upon completion of the expansion construction. Estimated rental payments for the expansion over the next five annual periods are as follows: 2026 (excluding the six months ended June 30, 2026) $ 1,034 2027 2,099 2028 2,162 2029 2,227 2030 2,294 2031 2,363 The lease of the existing building and certain real property sold is a failed sale-and-leaseback as a result of finance lease classification. The Company recorded a financing obligation equal to the $ 6,250 cash proceeds received. The Company allocated projected rental payments during the term of construction and fifteen-year lease term based on the estimated fair value of the existing real property assets and future expansion. The Company imputes interest monthly at a rate of 6.76 %. During the six months ended June 30, 2026, interest expense was not significant. 10 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) Future maturities of the financing obligation are projected as follows: 2026 (excluding the six months ended June 30, 2026) $ 55 2027 128 2028 152 2029 180 2030 209 2031 and thereafter 5,485 Total long-term financing obligation, of which $ 116 is current $ 6,209 The financing obligation is included in Other current liabilities and Other noncurrent liabilities on the Condensed Consolidated Balance Sheet. 7. LEASES The Company has operating and finance leases for office, manufacturing and warehouse facilities and automobiles. The Company’s leases have remaining lease terms of less than two years to ten years . Options to renew or extend leases beyond their initial term have been excluded from measurement of the right-of-use (ROU) assets and lease liabilities as exercise is not reasonably certain. The weighted average remaining lease term and the discount rate for the reporting periods are as follows: June 30, 2026 December 31, 2025 Operating Leases Weighted average remaining lease term (years) 4.8 5.1 Weighted average discount rate 7.0 % 7.0 % Finance Leases Weighted average remaining lease term (years) 4.2 4.7 Weighted average discount rate 7.0 % 7.0 % A letter of credit for $ 1,250 issued to the lessor of the Company's corporate headquarters building is renewed annually and remains outstanding as of June 30, 2026. The components of lease expense are as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Operating lease cost $ 471 $ 491 $ 1,001 $ 957 Finance lease cost: Amortization of right-of-use assets 261 262 523 524 Interest on lease liabilities 119 142 245 289 Total finance lease cost $ 380 $ 404 $ 768 $ 813 Short-term lease expense was not significant for the three and six months ended June 30, 2026 and 2025. 11 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) Supplemental cash flow information related to leases is as follows: Six Months Ended June 30, 2026 Six Months Ended June 30, 2025 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 1,011 $ 1,021 Operating cash flows for finance leases 245 289 Financing cash flows for finance leases 638 579 Right-of-use assets and corresponding lease obligations related to new and modified lease agreements: Operating leases $ 141 $ 1,891 Finance leases — — Supplemental balance sheet information related to leases is as follows: June 30, 2026 December 31, 2025 Operating Leases Operating lease right-of-use assets $ 6,069 $ 6,868 Other current liabilities $ 1,688 $ 1,734 Finance and operating lease liabilities 4,774 5,541 Total operating lease liabilities $ 6,462 $ 7,275 Finance Leases Property and equipment, at cost $ 14,750 $ 14,765 Accumulated depreciation ( 10,430 ) ( 9,922 ) Property and equipment, net $ 4,320 $ 4,843 Other current liabilities $ 1,369 $ 1,306 Finance and operating lease liabilities 5,274 5,975 Total finance lease liabilities $ 6,643 $ 7,281 Future maturities of lease liabilities as of June 30, 2026 are as follows: Operating Leases Finance Leases 2026 (excluding the six months ended June 30, 2026) $ 942 $ 892 2027 1,897 1,808 2028 1,489 1,842 2029 1,089 1,818 2030 681 1,339 2031 and thereafter 1,748 — Total payments $ 7,846 $ 7,699 Less imputed interest ( 1,384 ) ( 1,056 ) Total $ 6,462 $ 6,643 12 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) 8. COMMITMENTS AND CONTINGENCIES Cooperation Agreement. The Company holds an exclusive licensing agreement (Cooperation Agreement) to co-develop and commercialize equipment incorporating pulsed field ablation (PFA) technology. The Cooperation Agreement requires the Company to pay contingent consideration, settled in cash, with a maximum total payout of $ 28,000 if all milestones are achieved successfully through the agreement term ending in 2034. As of the reporting date, the Company has paid $ 6,000 towards milestone achievements which were recorded as research and development expense when each milestone was achieved. For the three and six months ended June 30, 2026, no milestones were achieved and therefore, there was no financial impact during the periods. For the three and six months ended June 30, 2025, payments made under the agreement were $ 5,000 . The agreement also contains provisions requiring future royalty payments on devices incorporating co-developed technology upon commercialization. Purchase Agreements. The Company enters into standard purchase agreements with suppliers in the ordinary course of business, generally with terms that allow cancellation. In 2022, the Company entered into a clinical trial management agreement for the LeAAPS clinical trial. The terms of the agreement require payments upon achievement of various enrollment and project milestones over the estimated ten-year term; however, the agreement may be terminated early for any reason. Furthermore, the Company incurs additional variable costs, including pass through costs from clinical trial sites. Payments made under this agreement were $ 1,299 and $ 3,375 for the three months ended June 30, 2026 and 2025 and $ 5,188 and $ 7,487 for the six months ended June 30, 2026 and 2025. In 2025, the Company entered into a non-cancellable cloud computing arrangement, as amended with a term of seven years requiring total payments of $ 5,593 . Payments made under this agreement were $ 258 for the three and six months ended June 30, 2026. For the three and six months ended June 30, 2025, there were no payments made during the periods. Legal. The Company may, from time to time, become a party to legal proceedings which are subject to many uncertainties. Litigation and administrative proceedings over patent and other intellectual property rights are common in our industry, as are requests for information related to interactions with medical professionals. Accordingly, the financial impact of ultimate resolutions from legal proceedings may not be known for extended periods of time and are not predictable with assurance. A liability is established once management determines a loss is probable and an amount can be reasonably estimated. The Company recognizes income from a favorable resolution of legal proceedings when the associated cash or assets are received. On February 7, 2025, the representative for former securityholders of SentreHEART, Inc. filed a complaint in the Delaware Court of Chancery naming the Company as a defendant, and on May 23, 2025 filed a first amended complaint. The Company acquired SentreHEART, Inc. pursuant to a merger agreement dated August 11, 2019. The merger agreement provides for contingent consideration to be paid upon achievement of specified PMA and CPT reimbursement milestones by specified dates. The amended complaint alleges breach of contract and a related claim for breach of the implied covenant of good faith and fair dealing resulting from the Company's alleged failure to use commercially reasonable efforts to obtain premarket approval from FDA for the LARIAT ® System. The amended complaint seeks damages in the amount of the original PMA and CPT reimbursement milestones of up to $ 260,000 plus interest. The Company intends to vigorously defend this claim. A liability has not been recognized related to this matter because any potential loss is not currently probable or reasonably estimable. 9. REVENUE The Company develops, manufactures and sells devices designed for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally and primarily used by cardiothoracic and thoracic surgeons. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. 13 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) United States revenue by product type is as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Open ablation $ 40,885 $ 36,468 $ 79,965 $ 69,776 Minimally invasive ablation 6,031 7,839 12,417 16,319 Pain management 27,058 21,168 49,417 38,438 Appendage management 51,614 45,108 99,994 87,199 Total United States $ 125,588 $ 110,583 $ 241,793 $ 211,732 International revenue by product type is as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Open ablation $ 11,243 $ 10,349 $ 20,759 $ 19,344 Minimally invasive ablation 2,020 2,372 3,933 4,385 Pain management 2,380 2,033 4,370 3,822 Appendage management 12,373 10,802 23,998 20,476 Total International $ 28,016 $ 25,556 $ 53,060 $ 48,027 Revenue attributed to customer geographic locations is as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 United States $ 125,588 $ 110,583 $ 241,793 $ 211,732 Europe 17,209 16,133 33,281 30,331 Asia Pacific 8,633 7,484 15,711 14,268 Other International 2,174 1,939 4,068 3,428 Total International 28,016 25,556 53,060 48,027 Total Revenue $ 153,604 $ 136,139 $ 294,853 $ 259,759 10. INCOME TAX PROVISION The Company files federal, state and foreign income tax returns in jurisdictions with varying statutes of limitations. The Company uses the asset and liability method to determine its provision for income taxes. The Company’s provision for income taxes in interim periods is computed by applying the discrete method and is based on financial results through the end of the interim period. The Company determined that using the discrete method is more appropriate than using the annual effective tax rate method. The Company is unable to estimate the annual effective tax rate with sufficient precision to use the effective tax rate method, which requires a full-year projection of income. The effective tax rate for the three months ended June 30, 2026 and 2025 was 5.0 % and ( 4.4 %). The effective tax rate for the six months ended June 30, 2026 and 2025 was 7.7 % and ( 4.0 %). The Company’s worldwide effective tax rate differs from the US statutory rate of 21% primarily due to valuation allowances. The Company's federal, state, local and foreign tax returns are subject to review by various taxing authorities. The Company has not accrued any interest and penalties related to unrecognized income tax benefits as a result of offsetting net operating losses. However, if required, the Company will recognize interest and penalties within income tax expense and within the related tax liability. 14 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) 11. EQUITY COMPENSATION PLANS The Company has two share-based incentive plans: the 2023 Stock Incentive Plan (2023 Plan) and the 2018 Employee Stock Purchase Plan (ESPP). Stock Incentive Plan Under the 2023 Plan, the Board of Directors may grant restricted stock awards or restricted stock units (collectively RSAs), nonstatutory stock options, performance share awards, performance share units or stock appreciation rights to Company employees, directors and consultants, and may grant incentive stock options to Company employees. The Compensation Committee of the Board of Directors, as the administrator of the 2023 Plan, has the authority to determine the terms of any awards, including the number of shares subject to each award, the exercisability of the awards and the form of consideration. As of June 30, 2026, 7,287 shares of common stock have been reserved for issuance under the 2023 Plan, and 3,251 shares were available for future grants. The Company issues registered shares of common stock for stock option exercises, restricted stock grants and performance share award payments. Employee Stock Purchase Plan Under the ESPP, shares of the Company’s common stock may be purchased at a discount ( 15 %) to the lesser of the closing price of the Company’s common stock on the first or last trading day of the offering period. The offering period (currently six months ) and the offering price are subject to change. Participants may not purchase more than $ 25 of the Company’s common stock in a calendar year or more than 3 shares during an offering period. As of June 30, 2026, there were 899 shares available for future issuance under the ESPP. Share-Based Compensation Expense Information The following table summarizes the allocation of share-based compensation expense: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Cost of revenue $ 747 $ 741 $ 1,430 $ 1,410 Research and development expenses 2,279 1,982 4,370 3,834 Selling, general and administrative expenses 9,287 8,648 17,786 15,757 Total $ 12,313 $ 11,371 $ 23,586 $ 21,001 15 Table of Contents ATRICURE, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In Thousands, except per share amounts) (Unaudited) 12. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share reflects net income available to common stockholders divided by the weighted average number of common shares outstanding during the period, including the effect of dilutive common share equivalents. Dilutive equivalents include shares issuable upon the vesting of restricted stock awards and restricted stock units, the exercise of stock options and shares issuable under the Company's employee ESPP. Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net income (loss) available to common stockholders $ 8,955 $ ( 6,190 ) $ 9,063 $ ( 12,937 ) Basic weighted average common shares outstanding 48,667 47,721 48,501 47,557 Effect of dilutive securities 201 — 593 — Diluted weighted average common shares outstanding 48,868 47,721 49,094 47,557 Basic net income (loss) per common share $ 0.18 $ ( 0.13 ) $ 0.19 $ ( 0.27 ) Diluted net income (loss) per common share $ 0.18 $ ( 0.13 ) $ 0.18 $ ( 0.27 ) The computation of diluted earnings per share in the three and six months ended June 30, 2026 excludes the effect of 2,807 and 1,162 shares because the effect would be anti-dilutive. The computation of diluted earnings per share in the three and six months ended June 30, 2025 excludes the effect of 2,930 shares because the effect would be anti-dilutive. 13. COMPREHENSIVE INCOME (LOSS) AND ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) In addition to net income (loss), comprehensive income (loss) includes foreign currency translation adjustments. Accumulated other comprehensive income (loss) consisted of the following, net of tax: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Total accumulated other comprehensive income (loss) at beginning of period $ 227 $ ( 230 ) $ 566 $ ( 1,035 ) Foreign Currency Translation Adjustment Balance at beginning of period $ 227 $ ( 230 ) $ 566 $ ( 1,035 ) Other comprehensive income (loss) before reclassifications ( 231 ) 1,640 ( 587 ) 2,357 Amounts reclassified to other income (expense) 105 ( 661 ) 122 ( 573 ) Balance at end of period $ 101 $ 749 $ 101 $ 749 Total accumulated other comprehensive income at end of period $ 101 $ 749 $ 101 $ 749 16 Table of Contents